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Abstract 
Autoantibodies to components of the nucleolus are a unique se-
rological feature of patients with scleroderma. There are auto-
antibodies of several specificities; one type produces a speckled 
pattern of nucleolar staining in immunofluorescence. In actino-
mycin D and 5,6-dichloro-{j-D-ribofuranosylbenzimidazole-
treated Vero cells, staining was restricted to the fibrillar and not 
the granular regions. By double immunofluorescence, specific 
rabbit anti-RNA polymerase I antibodies stained the same fi-
brillar structures in drug-segregated nucleoli as scleroderma sera. 
Scleroderma sera immunoprecipitated 13 polypeptides from 
(35S)methionine-labeled HeLa cell extract with molecular weights 
ranging from 210,000 to 14,000. Similar polypeptides were pre-
cipitated by rabbit anti-RNA polymerase I antibodies, and their 
common identities were confirmed in immunoabsorption exper-
iments. Microinjection of purified IgG from a patient with 
speckled nucleolar staining effectively inhibited ribosomal RNA 
transcription. Autoantibodies to RNA polymerase I were re-
stricted to certain patients with scleroderma and were not found 
in other autoimmune diseases. 
Introduction 
Patients with systemic autoimmune diseases spontaneously pro-
duce antibodies against a variety of cellular components (I). 
DNA and histones are among nuclear autoantigens with known 
structure and function. Other nuclear antigens are either nuclear 
proteins or RNA-protein complexes that have been partially 
characterized and called Ul-RNP, Srn, SS-B/La, Jo-I, Scl-70, 
and centromere/kinetochore antigens (2-10). There are expec-
tations that knowledge of the structure and function of these 
autoantigens could lead to a better understanding of the etio-
pathogenesis of autoimmune diseases and provide better reagents 
to construct accurate diagnostic probes. Furthermore, some of 
these naturally occurring autoantibodies have been used suc-
cessfully as probes in molecular and cellular biology. For ex-
ample, antibodies against UI-RNP were shown to inhibit splicing 
of heterogenous nuclear RNA, thus implicating an important 
role of this ribonucleoprotein in the processing of precursor 
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mRNA (11). Autoantibodies against SS-B/La identified this nu-
clear ribonucleoprotein as possibly involved in the transport of 
RNA, particularly products of RNA polymerase Ill, including 
virus encoded RNAs EBER I and 2 of Epstein-Barr virus (12). 
More recent evidence suggests that the SS-B/La particle is either 
a termination factor for RNA polymerase III or is involved in 
posttermination processing events (13). Recently, anticentro-
mere/kinetochore antibodies from scleroderma patients have 
facilitated identification and molecular cloning of a common 
human kinetochore protein (14). 
Antinucleolar antibodies are part of the spectrum of auto-
antibodies present in scleroderma (15-17). This systemic au-
toimmune disease is characterized by microvascular lesions and 
abnormalities of the immune system leading to fibrosis of the 
skin and certain target organs. One of the antigens reactive with 
scleroderma antibodies was recently shown to be a novel nu- . 
cleolar 7-2 ribonucleoprotein (18-19). U-3 ribonucleoprotein 
was also shown to be part of a complex precipitated by certain 
antinucleolar autoantibodies from scleroderma patients (18). 
These autoantibodies were found to interact with a basic nu-
cleolar protein of mol wt 34,000 (20), termed fibrillarin, as this 
protein was shown to be associated with the fibrillar component 
of nucleoli (21). The identity of other nucleolar autoantigens in 
scleroderma, however, is unknown. 
In this study, we present data that show that the antigens 
recognized by a subgroup of antinucleolar autoantibodies consist 
of RNA polymerase I complex. The clinical association of this 
antibody specificity was with the diffuse form of scleroderma. 
Methods 
Sera. Included in this study are sera from 208 scleroderma patients, 
kindly provided by O. P. Hornstein (Erlangen, FRG), H. Mensing 
(Hamburg, FRG), M. Meurer (Munich, FRG), D. S. Prince (Birmingham, 
AL), R. A. Kaplan (San Diego, CA), J. G. Curd and G. W. Williams (La 
Jolla, CA). Sera from more than 100 patients with other systemic au-
toimmune diseases, including systemic lupus erythematosus (SLE),' 
mixed connective tissue disease (MCTD), drug-induced lupus, derma-
tomyositis, polymyositis, and rheumatoid arthritis, and 20 normal in-
dividuals served as controls. All scleroderma patients fulfilled the prelim-
inary criteria for the diagnosis of progressive systemic sclerosis (22). A 
rabbit antiserum to RNA polymerase I was used as a reference. This 
antiserum was produced in the laboratory of Or. K. M. Rose by im-
munization of a rabbit with purified RNA polymerase I from Morris 
hepatoma 3924 A in a manner described previously (23). Rabbit anti-
RNA polymerase I antibodies, as used in the present study, had previously 
been used in a series of other studies to localize RNA polymerase I in 
normai cells (24) and cells treated with the nucleolus segregating drug 
5,6-dichloro-iJ-D-ribofuranosylbenzimidazole (ORB) (25). These anti-
bodies had been used further to show induction of increased amount 
I. Abbreviations used in this paper: DRB, 5,6-dichloro-iJ-D-ribofura-
nosylbenzimidazole; MCTD, mixed connective tissue disease; PMSF, 
phenylmethylsulfonylfluoride; SLE, systemic erythematosus. 
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and activity of RNA polymerase I in mouse B lymphocytes treated with 
lipopolysaccharide (26). 
Indirect immunofluorescence. Indirect immunofluorescence was 
performed with Hep-2 cells (Bion Enterprises, Ltd., Park Ridge, IL) as 
substrate. Other substrates included HeLa and Vero cells, grown on mi-
croscopic slides and fixed in ice cold acetone/methanol 3: I for 3 min, 
and rat liver cryostat sections. Further tissues included chicken liver and 
different organ sections from Xenopus laevis. Sera were diluted starting 
at I :40 in phosphate-buffered saline (PBS), pH 7.4. A fluorescein (Behring 
Diagnostic, La Iolla, CA) and a rhodamine-Iabeled goat anti-human 
IgG conjugate (Tago, Inc., Burlingame, CA) were used. A fluorescein-
labeled goat anti-rabbit IgG conjugate was obtained from Tago, Inc. 
Intensity of immunofluorescence staining was graded weak (+), moderate 
(++), or strong (+++). Results were read on an Ortholux II fluorescence 
microscope with a Ploempak vertical illuminator (E. Leitz, Inc., Rock-
leigh, NI) using a NPL Auortar 100/1.32 oil immersion objective. Double 
immunofluorescence staining was performed as described (27). 
Drug studies. Segregation of nucleoli in tissue culture Vero cells into 
fibrillar and granular regions was induced by the addition of 0.2 /Lg/ml 
actinomycin D to the culture medium for 4 h or of 50 /Lg/ml DRB, a 
halogenated adenosine analogue, for 6 h. Both drugs were purchased 
from Behring Diagnostics. After drug treatment, cells were fixed in ace-
tone/ methanol 3: I and processed for immunofluorescence as described 
above. 
Electron microscopic immunocytochemistry. Frozen sections (5-/Lm 
thickness) of normal and regenerating rat liver were fixed in acetone at 
- 20°C for 10 min, air dried, and incubated with scleroderma serum S 18 
or rabbit anti-RNA polymerase I antibodies diluted I: lOO in PBS for 2 
h. After several washes in PBS, goat anti-human IgG or goat anti-rabbit 
IgG coupled to colloidal gold (5-nm diameter; Ianssen Life Sciences 
Products, Beerse, Belgium) was added at a dilution of I :4. After overnight 
incubation at 4°C, the specimens were fixed and processed for electron 
microscopy as described in detail elsewhere (24). 
Radiolabeling of cells. HeLa cells were cultured in monolayers and 
radiolabeled for 20 h with [35S)methionine or f 2p)orthophosphate (New 
England Nuclear, Boston, MA) at 0.1 mCi/ml in methionine- or phos-
phate-free medium, respectively, as described (28). The cells were then 
washed once in PBS and harvested with a rubber policeman in ice cold 
buffer A containing 10 mM Tris-HCI (pH 7.4), 150 mM NaCl, 1.5 mM 
MgCh , 0.5% Nonidet P-40, supplemented with 23 U/ml kallikrein in-
activator (Behring Diagnostics) and 2 mM phenylmethylsulfonylfluoride 
(PM SF) to minimize proteolytic degradation. The cells were then freeze-
thawed twice and centrifuged at 10,000 g for 15 min, and the supernatant 
was stored at - 70°C until used. -10 mg protein were extracted from 
HeLa cells grown in 150 X 25-mm tissue culture dish. 
Immunoprecipitation. All experiments were performed at 0-4°C as 
described (28) with modifications. In brief, serum aliquots of 10 /LI were 
incubated with 100 /Ll of protein A Sepharose CL-4B (Pharmacia, Inc. , 
Uppsala, Sweden) at 10% (vol/vol) suspension in buffer B supplemented 
with 2 mg/ml bovine serum albumin. Buffer B contained 50 mM Tris-
HCI (pH 7.4), 150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P-40, 0.5% 
sodium deoxycholate, and 0.1 % sodium dodecyl sulfate (SDS). After 
washing five times in 1.5 ml buffer B, lOO /Lg radiolabeled HeLa cell 
protein extract was added to the beads and incubated for I h with constant 
mixing. The radiolabeled extract had been precleared with 1/10 vol of 
protein A Sepharose CL-4B in buffer B before being used. After centrif-
ugation for 3 min, the pellet was washed five times in 1.5 ml buffer B 
containing 23 U/ml kallikrein inactivator and 2 mM PMSF. The 
[35S)methionine-labeled pellet was then boiled in Laemmli sample buffer, 
and the proteins were analyzed by SDS-polyacrylamide gel electropho-
resis (PAGE) (29), followed by fluorography and autoradiography. Half 
of the 32P-labeled pellet was digested with DNase and RNase (Millipore 
Corp., Bedford, MA) at 0.5 mg/ml each for 30 min at 3rC, and the 
proteins were resolved by SDS-PAGE. The other half of the pellet was 
phenol extracted, and any RNA was precipitated in ethanol. RNA analysis 
was performed in 7 M urea, 8% polyacrylamide gels, then autoradiography 
as described elsewhere (2). 
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Antigen depletion. [35S)methionine-labeled HeLa cell extract (100 /Lg 
of protein) was incubated with 40 /Lg rabbit anti-RNA polymerase I IgG 
bound to protein A Sepharose CL-4B for I hat 4°C in buffer B to deplete 
the extract of RNA polymerase I. The depleted supernatant was then 
used in immunoprecipitation as the antigen source for human anti nu-
cleolar sera. In another experiment, [35S)methionine-Iabeled HeLa cell 
extract was absorbed with 40 /Lg human antinucleolar IgG as described 
and then probed with rabbit anti-RNA polymerase I. The same amounts 
of IgG from normal human serum and normal rabbit serum, as well as 
from a SLE serum with Srn specificity, were included in control exper-
iments to ensure that changes observed were not due to nonspecific pro-
tein-protein interactions. 
Microinjection of antibodies into X. laevis oocytes. IgG was obtained 
from a representative scleroderma serum (S 18) by column chromatog-
raphy on DEAE-cellulose (DE-52; Whatman Inc., Clifton, NI) and was 
further purified by chromatography on protein A-Sepharose (Sigma 
Chemical Co., St. Louis, MO). IgG was concentrated to 2 mg/ml by 
vacuum dialysis against PBS. Antibodies were microinjected into nuclei 
of full-grown oocytes of X. laevis as described (30). Each oocyte nucleus 
received 10 nl antibody solution. In some experiments, the solution was 
injected into the cytoplasm of the animal hemisphere of the oocytes. 
Purified IgG from normal human sera or monoclonal antibodies reacting 
with nonnucleolar constituents of oocytes were used as controls. Each 
experimental group consisted of six oocytes. 2 h after antibody injection, 
each oocyte received O. I/LCi a _[32P)GTP (10 mCi/ml; Amersham Buchler 
GmBH, Braunschweig, FRG) by injection into the cytoplasm. After an 
incubation time of 6 h at 20°C, RNA was extracted and analyzed by 
electrophoresis in 1.5% agarose gels as described (30). The RNA corre-
sponding to two oocytes was applied to each gel lane, air dried, and 
identified by autoradiography. rRNA from X. laevis ovary ribosomes 
and RNA from tobacco mosaic virus served as molecular weight markers. 
Results 
Antinucleolar antibodies in scleroderma sera. IgG antinucleolar 
antibodies were present in 31 of 208 scleroderma sera (15%). 
These sera were selected for strong (+++) nucleolar staining by 
indirect immunofluorescence on substrate Hep-2 cells. Nucleo-
plasmic staining was also present with some sera, but the des-
ignation of sera with antinucleolar antibodies in this screening 
assay was based on the criterion that nucleolar staining exceeded 
nucleoplasmic staining by at least one gradation of intensity. 
Nine of the antinucleolar positive sera gave a punctate or speck-
led nucleolar staining pattern, usually up to a serum dilution of 
I :2,560 or higher. The other sera produced homogeneous or 
c1umpy nucleolar staining and were classified according to a 
previous report on the association of antinuclear and anti nu-
c1eolar antibodies in scleroderma (17). 
In the present study, the antigen reactive with scleroderma 
antibodies that produce speckled nucleolar staining was further 
characterized. 
Localization by light and electron microscopic immunocy-
tochemistry of scleroderma antibodies with speckled nucleolar 
staining. The following immunofluorescence results were ob-
tained with all nine sera with speckled nucleolar staining. Fig. 
I shows indirect immunofluorescence staining and phase-con-
trast microscopy as obtained with representative serum SI8 using 
HeLa cells (a and b), Vero cells (c and d), and concanavalin-A-
stimulated human peripheral blood lymphocytes (e and f) as 
substrates. Note that in different phases of the cell cycle, different 
staining patterns were observed. Nucleolar staining that consisted 
of many fluorescent speckles in interphase cells changed to a 
few bright fluorescent spots in the area of condensed chromo-
somes of dividing cells (Fig. I c, arrows). In concanavaJin-A-
stimulated peripheral blood Iymphocytes, increased intensity of 
nucleolar staining was observed in blast-transformed Iympho-
cytes (Fig. I e. large cells). Weak nucleoplasmic staining (+) of 
interphase cells was also observed with these sera, whereas cy-
toplasmic staining was usually absent. 
To further define the nature of the nucleolar antigens, we 
exposed Vero cells to the nucleolus-segregating drugs actino-
mycin D and DRB. After drug treatment, cells were processed 
for indirect immunofluorescence and phase-contrast micros-
copy. Actinomycin D-inactivated nucleoli show a typical seg-
regation of the fibrillar component from the granular component 
(Fig. 2 b), with the fibrillar component forming distinct nucleolar 
hemispheres (31-33). Antibodies demonstrating speckled nu-
c1eolar staining in untreated cells were now distinctly localized 
in the fibrillar regions of segregated nucleoli (Fig. 2 a). Immu-
nofluorescence staining was most prominent in small crescents 
at the outermost margins of the segregated fibrillar component. 
Little if any decoration of the granular structures that appeared 
dark in phase optics was observed. When DRB was added to 
Vero cells growing in culture, the normally compact nucleoli 
unraveled into extended beaded strands, segregating the nucleo-
lus into granular and fibrillar regions (34, 35). Immunofluores-
cence staining of these cells using the same scleroderma anti-
Figure 1. Immunofluorescence microscopy of 
HeLa cells (a), Vero cells (c), and concanavalin 
A stimulated peripheral human blood lympho-
cytes (e) after staining with antinucleolar anti-
bodies (S 18) from a patient with scleroderma. 
Nucleoli demonstrate a speckled immunofluo-
rescence pattern of interphase cells. In a mitotic 
Vero cell, several bright fluorescent dots (ar-
rows) are present that may represent nucleolar 
organizer regions. Weak nucleoplasmic staining 
is also present. Note increase of nucleolar stain-
ing in blast-transformed lymphocytes (large 
cells in e and!). For comparison, the cells are 
also shown in phase contrast optics (b. d.!) . 
Bar, 20 /Lm X 1,450. 
bodies resulted in binding with only fibrillar structures producing 
a "necklace" distribution of fluorescent dots dispersed through-
out the nucleoplasm (Fig. 2, c and d). 
Electron miscroscopy was performed using reference serum 
SI8 and rabbit anti-RNA polymerase I antibodies in the im-
munogold label technique. In this experiment, gold-antibody 
complexes were localized in the fibrillar centers of nucleoli in 
hepatocytes from normal and regenerating rat liver. IgG from 
scleroderma serum S 18 was selectively enriched over the fibrillar 
centers and was not observed in the dense fibrillar component 
or the granular component of nucleoli (Fig. 3, a and b). The 
same staining pattern was obtained with a rabbit anti-RNA 
polymerase I serum (Fig. 3 c) showing distribution of gold-an-
tibody complexes in the fibrillar centers, as had been reported 
previously (24). 
Interaction of antinucleolar antibodies from scleroderma 
sera with RNA polymerase I 
Double immunofluorescence staining. The enzyme RNA poly-
merase I has been shown by other investigators to be localized 
in nucleoli. The immunofluorescence patterns obtained with 
the human scleroderma sera depicted in Figs. I and 2, as well 
as the electron microscopic studies in Fig. 3, are morphologically 
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Figure 2. Cultured Vero cells were treated with nucleolus-segregating 
drugs actinomycin D (a and b) or DRB (c and d) and processed for 
indirect immunofluorescence and phase-contrast microscopy. In acti-
nomycin D segregated nucleoli, scleroderma antibodies SI8 selectively 
stained the fibrillar regions, as shown in (a) of this composite. Immu-
nofluorescence staining is most prominent in two small crescents (ar-
similar to those obtained with rabbit anti-RNA polymerase I 
antibodies (24, 25). It remained to be demonstrated that identical 
subcellular structures were reactive with both antibodies by si-
multaneous staining. A human serum representative of speckled 
nucleolar staining (SIS) and anti-RNA polymerase I rabbit 
serum were incubated simultaneously with Vero cells treated 
with ORB. The antigen-antibody reaction was visualized on the 
same substrate with a rhodamine anti-human IgG and fluores-
cein anti-rabbit IgG conjugate. In this experiment it was observed 
that both human antinucleolar and rabbit serum recognized the 
same nucleolar structures in location and conformation, so pho-
tomicrographs from these experiments were virtually superim-
po sable (data not shown). 
Immunoprecipitation. We then examined the molecular na-
ture of the antigen reactive with human sera demonstrating 
speckled nucleolar staining. e SS]methionine-labeled HeLa cell 
extract was used for immunoprecipitation. Nine sera with 
speckled nucleolar staining pattern uniformly immunoprecipi-
tated 13 polypeptides (PI-PI3) with mol wt of21O,000, 190,000, 
155,000, 130,000, 120,000, SO,OOO, 64,000, 62,000, 42,000, 
25,000, IS,OOO, 16,000, and 14,000. The results obtained with 
two representative sera (SIS and S124) are shown in Fig. 4 a, 
lanes 2 and 3. Examination of the immunoprecipitates obtained 
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rows) at the outermost margins of the fibrillar regions. The dark (by 
phase contrast) granular component in the center of this compact nu-
cleolus (b) is essentially unstained. In Vero cells treated with DRB, 
S 18 antibodies give a necklace type of staining dispersed throughout 
the nucleoplasm (c). The same cell is also shown by phase-contrast mi-
croscopy (d) . Bar, 20 }.LID X 1,450. 
by the rabbit anti-RNA polymerase I antibodies side by side 
with the human antinucleolar antibodies revealed the same 13 
polypeptides by SOS-PAGE and autoradiography (Fig. 4, lane 
4). Fig. 4 b shows the same polypeptides as Fig. 4 a, but better 
resolution of the high molecular weight polypeptides PI-P6 was 
obtained in 5% SOS-polyacrylamide gel instead of 17.5% gel. 
Our control group, consisting of normal human sera and more 
than 100 autoimmune sera from patients with systemic lupus 
erythematosus, MCTD, or rheumatoid arthritis did not contain 
antibodies precipitating this 'Polypeptide profile. Moreover, none 
of the sera from 120 SLE patients analyzed by immunoprecip-
itation in another study in this laboratory (manuscript in prep-
aration), precipitated these 13 polypeptides. On the other hand, 
this pattern of 13 polypeptides was consistently produced by 
nine sera with speckled nucleolar immunofluorescence. Sera with 
other patterns of nucleolar reaction also did not produce this 
finding. 
HeLa cells were labeled with [32p]orthophosphate and the 
cell lysate used to determine if any of the RNA polymerase I 
subunits were phosphoproteins and whether this enzyme was 
coprecipitated with any species of RNA. The polypeptides of 
mol wt 190,000 (P2), SO,OOO (P6), 64,000 (P7), and IS,ooo (PI I) 
were phosphorylated as shown in Fig. 5, lane 4. This figure also 
shows that a phosphoprotein of mol wt 35,000 (arrow), which 
was not labeled with [35Sjmethionine, was precipitated as a 
phosphoprotein by S 18 antibodies. In this series of experiments, 
a longer gel (15 cm vs. 8.5 cm) was used to identify unambig-
uously the 32P-labeled proteins. In many studies using acid-urea 
gels (see Methods), RNA was not coprecipitated with the RNA 
polymerase I complex, as opposed to anti-V I RNP antibodies 
from a patient with MCTD, which precipitated the VI-RNA 
species (data not shown). 
Immunoabsorption. To demonstrate further that the human 
antinucleolar and rabbit anti-RNA polymerase I antibodies in-
teract with the same antigen, i.e., RNA polymerase I, we absorbed 
(35Sjmethionine-labeled HeLa cell extract with the IgG fraction 
of rabbit antiserum. We then used this RNA polymerase I-de-
pleted extract in an immunoprecipitation assay and showed that 
this preparation lacked the antigen recognized by our prototype 
antinucleolar serum S 18 (Fig. 6, lane 2). In a reciprocal fashion, 
when HeLa cell extract was absorbed with this human serum 
and then probed with rabbit antiserum, the RNA polymerase I 
Figure 3. Binding of scleroderma antinucleo-
lar IgG S 18 (a and b) and rabbit antibodies to 
RNA polymerase I (c) to subnucleolar com-
ponents in the hepatocytes of normal (a and 
c) and regenerating (b) rat liver, as revealed 
by the electron microscopic immunogold la-
bel technique. The 5-nm gold particles (small 
black dots) are selectively enriched over the 
fibrillar centers (FC), roundish zones of low 
contrast. The dense fibrillar components 
(DFC) surrounding the fibrillar centers as 
well as the granular components (GC) of the 
nucleoli are essentially free of gold particles 
after incubation with both antibodies. (Ch), 
chromatin surrounding the nucleoli. Bars, 0.1 
!lm X 110,000 (a, b), 0.1 !lm X 135,000. 
complex was not precipitated (Fig. 6, lane 4). In contrast, de-
pletion of radiolabeled HeLa cell extract by autoantibodies of 
different immunological specificities, e.g., anti-Srn antibodies as 
in lane 5, did not affect specific antigen recognition by antinu-
c1eolar scleroderma (Fig. 6, lane 6) or rabbit anti-RNA poly-
merase I IgG (data not shown). These findings support the earlier 
observations that RNA polymerase I is the antigen recognized 
by certain antinucleolar antibodies in scleroderma sera. 
·Microinjection of antibodies into Xenopus laevis oocytes. 
Purified IgG from reference serum S 18 and control antibodies 
were microinjected into X. laevis oocyte nuclei. In these exper-
iments, a considerable reduction in the accumulation of newly 
synthesized 28S and 18S rRNA was observed as shown in Fig. 
7, lane 4. This 1.5% agarose gel also shows that there was no 
significant effect when normal human serum IgG (lane 1) or 
monoclonal IgM antibody to DNA (lane 2) were injected into 
the nucleus of X. laevis oocytes. The monoclonaI IgM antibodies 
to DNA did not interfere with transcription of the rRNA genes 
because they are excluded from the compact amplified nucleoli. 
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2 3 4 5 Figure 4. (A) Autoradio-
L200 gram of immunoprecipi-I tated [35S)methionine-Ia-beled HeLa cell proteins 
... ,97.4 
resolved in a 17.5% 
-.., -69 
SOS-polyacrylamide 
-
"'" --46 gel. Normal human 
serum (lane 1). Repre-
sentative antinucleolar 
-30 scleroderma sera (S 18 
- -PlO and S124) with speckled 
-Pll 
staining pattern (lanes 2 
-P12 and 3, respectively). 
- P13 Rabbit anti-RNA poly-
-12.3 merase I antibodies 
A (lane 4). Normal rabbit 
serum (lane 5). The rab-
bit anti-RNA polymer-Pl ___ 
- -200 ase I and antinucleolar P2-
---
scleroderma antibodies 
from two representative 
P3- patients precipitated the 
P4- same 13 polypeptides 
P5-
-116.2 (PI-PI3) of 210,000 to 14,000 mol wt that were 
B -92.5 
distinct from polypep-
tides of 70,000, 46,000, 
and 30,000 mol wt pre-
cipitated by normal human serum. In addition, control rabbit serum 
also brought down a protein of 80,000 mol wt. The 46,000 mol wt 
protein is actin, the other polypeptides precipitated by normal sera 
are unknown. (B) Autoradiogram of immunoprecipitated 
pSS)methionine-labeled HeLa proteins resolved in a 5% SOS-poly-
acrylamide gel. Antinucleolar scleroderma serum S 18 (lane 1). Rabbit 
anti-RNA polymerase I antibodies (lane 2). Normal human serum 
(lane 3). This low-percent gel system was used to demonstrate that dis-
tinct high molecular weight polypeptides of mol wt 210,000 (P I), 
190,000 (P2), 155,000 (P3), 130,000 (P4), 120,000 (P5), and 80,000 
(P6) were immunoprecipitated with the rabbit and the human antinu-
cleolar serum. 
However, they inhibit transcription of the lampbrush chromo-
some loops (data not shown). Microinjection of antibodies S 18 
into the cytoplasm (lane 3) also had no effect on rRNA tran-
scription since antibodies do not migrate through the nuclear 
pores (36). 
Several attempts were made to identify the epitope or epi-
topes of the RNA polymerase I complex reactive with certain 
scleroderma autoantibodies. Extractable whole HeLa cell pro-
teins, isolated nucleoli as well as purified RNA polymerase I 
from Morris hepatoma 3942A, were electrophoretically trans-
ferred to nitrocellulose for immunoblotting. At present, no con-
clusive results concerning the antigenic subunit were obtained, 
although a protein of mol wt 190,000 corresponding to one of 
the large subunits of RNA polymerase I from Morris hepatoma 
3924A has been weakly reactive with some sera. 
Discussion 
In the present study, we have provided evidence by immuno-
cytochemical localization, immunoprecipitation, and microin-
jection of auto immune antibodies into living cells that the RNA 
polymerase I complex was the antigen recognized by a subset 
of antinucleolar antibodies from scleroderma sera. Anti-RNA 
polymerase I autoantibodies were present in 4% of the 208 
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Figure 5. Autoradiogram of 
immunoprecipitated 
2 3 4 [35S)methionine- (lanes 1 and 
3) and [32p)orthophosphate-Ia-
200-
-P2 beled (lanes 2 and 4) HeLa cell 
proteins digested with RNase 
97.4- and DNase. Normal human 
69- -P6 serum (lanes I and 2). Antinu-
-P7 cleolar serum S 18 (lanes 3 and 
4). The polypeptides of mol wt 
46- 190,000 (P2), 80,000 (P6), 64,000 (P7), and 18,000 (PI I) 
labeled with S-methionine are 
also phosphoproteins. An addi-
30- - tional phosphoprotein of mol 
wt 35,000, not labeled with 
-. [3SS)methionine, is detected by 
autoradiography (arrow). This 
-Pll study used a longer gel (15 cm 
vs. 8.5 cm) to identify unam-
~. biguously the [32P)labeled pro-12.3- teins. The PI-PI3 RNA poly-
merase I complex in this and 
subsequent figures are identi-
fied by black dots. 
scleroderma patients examined and were found to be restricted 
to this autoimmune disease. 
RNA polymerase I is an enzyme complex transcribing the 
genes that code for the precursor molecules of ribosomal RNA 
(31 , 37). The distribution of this enzyme in interphase cells and 
mitotic chromosomes was recently studied by Scheer and Rose 
(24) and Scheer et al. (25). These investigators used an antiserum 
against RNA polymerase I from a rabbit immunized with the 
purified enzyme. By immunofluorescence microscopy, they ob-
tained a punctate nucleolar staining pattern in interphase cells 
from different species. They suggested that these punctate areas 
represented transcriptional complexes of RNA polymerase I and 
rRNA genes. During mitosis, RNA polymerase I molecules were 
detected at the chromosomal nucleolus organizer regions. Tran-
2 3 4 5 6 
-200 
-97.4 
-69 
A 
_.-._ .-30 
:-12.3 
Figure 6. Depletion of 
RNA polymerase I from 
[35S)methionine-Iabeled 
HeLa cell extract by rabbit 
and human antibodies. 
RNA polymerase I immu-
noprecipitated by rabbit an-
tibodies (lane 1). Immuno-
precipitate obtained with 
human antinucleolar anti-
bodies S 18 (lane 2) with su-
pernatant from lane 1 ex-
periment. Immunoprecipi-
tate obtained with 
antinucleolar antibodies 
S 18 with unabsorbed ex-
tract (lane 3). Immunopre-
cipitate obtained with rabbit 
anti-RNA polymerase I antibodies with supernatant from lane 3 ex-
periment. Anti-Srn serum from a patient with SLE showed a different 
immunoprecipitation profile (proteins A-G, lane 5). The supernatant 
from lane 5 experiment still contained the entire RNA polymerase I 
complex that was immunoprecipitated with serum SI8 (lane 6). 
2 3 4 
-40 S 
-28 S 
-18 S 
Figure 7. Autoradiogram of RNA 
from X. laevis oocytes radiolabeled af-
ter microinjection of various antibod-
ies. Intranuclear injection of mono-
clonal IgM-antibody to ONA (lane 2). 
Injection of purified IgG from sclero-
derma serum S 18 into the cytoplasm 
(lane 3) and nucleus (lane 4). Intro-
duction of the scleroderma antibodies 
S 18 into the oocyte nuclei causes a 
considerable reduction in the accumu-
lation of newly synthesized 28S and 
18S RNAs. 40S indicates position of 
the pre-rRNA. 
scriptionally active rRNA genes were localized by electron mi-
croscopic immunocytochemistry in the fibrillar centers of nu-
cleoli. 
The speckled nucleolar staining pattern we observed with a 
subset of antinucleolar antibodies from scleroderma patients was 
very similar to, if not identical with, the pattern described for 
the rabbit anti-RNA polymerase I serum by Scheer and Rose 
(24). An anti-RNA polymerase I serum from a rabbit was also 
used in a series of experiments in this study. Double immuno-
fluorescence staining showed that human speckled antinucleolar 
IgG decorated the same nucleolar structures as the rabbit anti-
bodies. Localization of autoantibodies in the fibrillar regions of 
drug-segregated nucleoli and, more importantly, their localiza-
tion by electron microscopy in fibrillar centers (24), which are 
the sites of rRNA gene transcription, gave confirming evidence 
of binding with RNA polymerase I. Interestingly, these sclero-
derma antibodies produced nucleolar immunofluorescence 
staining not only in human but also in rodent, avian, and am-
phibian cells, suggesting that the epitope is highly conserved 
during evolution. When scleroderma antibodies with speckled 
nucleolar staining in indirect immunofluorescence were mi-
croinjected into X. laevis oocytes, a dramatic decrease in the 
accumulation of newly transcribed ribosomal RNA was ob-
served. The human antibodies thus appear to be effective in 
interfering with the function of RNA polymerase I. 
On a macromolecular level, both scleroderma antinucleolar 
antibodies and rabbit anti-RNA polymerase I antibodies im-
munoprecipitated identical polypeptides ranging from mol wt 
210,000 to 14,000. RNA polymerase I is a complex enzyme 
previously reported to be composed of eight subunits in Morris 
hepatoma 3942A ranging in size from mol wt 190,000 to 17,500 
(23). By immunoprecipitation with specific antibody, we revealed 
five additional [35S]methionine-labeled polypeptides present in 
HeLa cell extract that had not been reported to be part of the 
enzyme purified by column chromatography from rat hepatoma. 
Further investigations will determine whether these additional 
polypeptides are part of the RNA polymerase I complex reflecting 
additional subunits or merely posttranslational modifications of 
previously described subunits. It is also conceivable that some 
of these additional polypeptides represent tightly bound factors 
of this enzyme that may be associated with initiation or termi-
nation ofrRNA gene transcription (38). Recently, immunopre-
cipitation of intrinsically radiolabeled DNA polymerase a with 
a monoclonal antibody resulted in the identification of an ad-
ditional catalytic component of this enzyme that had been pre-
viously unknown (39). It seems likely that the use of specific 
antibody for immunoprecipitation will also facilitate further 
characterization of RNA polymerase I. 
In a previous study, all RNA polymerase I subunits from 
rat hepatoma could be phosphorylated by an endogenous protein 
kinase associated with this enzyme (40-41). Autoradiography 
of in vivo 32P-Iabeled RNA polymerase I obtained by immu-
noprecipitation in this study revealed only four phosphoproteins 
(P2, P6, P7, and P I I) as part of the complex. Since the degree 
of phosphorylation ofthis enzyme paralleled transcriptional ac-
tivity as shown in previous studies (23, 40), the present findings 
might reflect a less active form of RNA polymerase I readily 
extractable from HeLa cells. At present it is unknown how exactly 
the phosphorylation is regulated in vivo. 
In previous reports by Stetler and co-workers (40, 42), an-
tibodies to RNA polymerase I were detected by radioimmu-
noassay and by immunoblotting in 100% of patients with SLE 
and MCTD, and in 78% of patients with rheumatoid arthritis. 
However, we were only able to immunoprecipitate the RNA 
polymerase I complex with scleroderma sera that produced a 
speckled nucleolar immunofluorescence pattern and not with 
any other sera, including scleroderma sera with different staining 
patterns. The discrepancies between the work of Stetler and as-
sociates and this study may be related to differences in techniques 
used. A critical assay used by the previous authors was a ra-
dioimmunoassay in which they employed a preparation of rodent 
RNA polymerase I as the antigen to coat the wells of plastic 
immunoassay plates. In the present study, immunocytochemical 
localization of antibody, immunoprecipitation of intrinsically 
labeled antigens, and microinjection of antibody into living cells 
were the main techniques used. These considerations, however, 
do not completely clarify the discrepancies. If RNA polymerase 
I, however, is an enzyme predominantly localized in the nu-
cleolus, as has been previously shown (24, 25, 31,37), it is difficult 
to understand why sera from SLE, MCTD, and rheumatoid ar-
thritis patients rarely demonstrate nucleolar staining in indirect 
immunofluorescence (15-17). It would be reasonable to expect 
that many SLE, MCTD, and rheumatoid arthritis sera would 
show nucleolar staining with the high frequency of anti-RNA 
polymerase I antibodies reported by the previous investigators. 
Several explanations concerning these discrepancies are now 
under investigation and they include the possibility that epitopes 
recognized by SLE, MCTD, and rheumatoid arthritis sera may 
not be accessible to antibody in the indirect immunofluorescence 
or immunoprecipitation assays. 
The association of speckled nucleolar staining by serum an-
tibodies with the diagnosis of scleroderma was noted in an earlier 
study (17). We have extended the studies to show that the reactive 
antigen demonstrates properties very similar to RNA polymerase 
I. Our knowledge of the function of this key enzyme in the 
nucleolus and the further characterization of the epitope may 
lead to another step in elucidating the immune response in 
scleroderma. 
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